基本震的治疗:一个系统的审查和基于贝叶斯模型的RCT的网络元分析
Junjiao Zhang1, Rui Yan1, Yusha Cui1
1Center for movement disorders, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
EClinicalMedicine
|November 5, 2024
概括
像CX-8998,propranolol和atenolol这样的基本震 (ET) 治疗方法显示出有效性和安全性. 深度大脑刺激 (DBS) 对严重的ET非常有效,但由于证据水平较低,需要进行更多研究.
科学领域:
- 神经学 神经学
- 临床治疗学 临床治疗学
- 医疗干预 医疗干预
背景情况:
- 基本震 (ET) 显著影响患者的生活质量,并带来临床挑战.
- 对ET的新型治疗方案在随机对照试验 (RCT) 中越来越多地被探索.
研究的目的:
- 系统地评估和比较各种干预措施对基本震的相对有效性和安全性.
- 为优化ET治疗策略提供基于证据的见解.
主要方法:
- 一项系统性审查和贝叶斯网络对33项涉及1251名患者的RCT进行的meta-analysis (NMA).
- 分析包括口服和非口服ET治疗,通过标准化平均差异 (SMD) 评估疗效,并使用日志概率比率 (log ORs) 评估安全性.
- 累积排名曲线下的表面 (SUCRA) 用于对治疗疗效进行排名.
主要成果:
- 与安慰剂相比,深度大脑刺激 (DBS),CX-8998,阿提诺洛尔和普拉诺洛尔显示出相对有效性.
- 根据Sucra排名,DBS显示了最高的相对疗效,其次是CX-8998,thalamotomy和atenolol.
- 由于安全数据的限制,除了DBS和thalamotomy外,最有效的治疗方法与安慰剂没有显著的安全差异;然而,GRADE评估表明证据水平低至非常低.
结论:
- CX-8998,醇和阿提诺醇是ET治疗的有效和安全选择.
- DBS对抗药性ET非常有效,但由于安全性数据有限和证据不足,需要谨慎应用.
- 进一步的大规模,对头的RCT对于确认发现和指导基本震管理的临床实践至关重要.
更多相关视频
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
442
07:14A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
Published on: May 31, 2016
14.7K
相关概念视频
Parkinson's Disease: Treatment
224
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
224
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
